When I was a medical student and junior doctor in the early 1980s I saw many patients on the wards in hospital with this terrible illness for which we could do little. When the heart fails as a pump one of the main manifestations is accumulation of fluid due to retention of sodium and water by the kidneys which also malfunction as a result of reduced blood flow and other mechanisms. Fluid accumulation in the legs and lungs leads to swelling (peripheral oedema) and breathlessness. Reduced blood flow to the muscles also causes intense fatigue. Back in these early days diuretics which caused the kidneys to produce more urine and relieve fluid intention) and digoxin, a 200 year old plant-extract thought to stimulate contraction of the failing heart, were the only two treatments we had, except for the rare, young, patient who was lucky enough to get a transplant. Otherwise, I knew that around 7 out of 10 of those men and women I saw would be dead within a year. Even worse the last months of their lives were characterized by disabling symptoms and exercise intolerance making even ordinary everyday activities a struggle, if not impossible. Often patients were also readmitted to hospital because of acute worsening of their symptoms. Around the time I graduated from medical school USA and European investigators such as Jay Cohn, Gary Francis, Peter Harris, and Philip Pool-Wilson were beginning to unravel the pathophysiology-the disease mechanisms-of heart failure and starting to explore the possibility of finding new treatments for this condition.
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1,2 The picture that emerged was remarkable. Although the primary problem was of course weakness and failing of the contraction of the heart muscle, it was the secondary responses (and their effects on the blood vessels, kidneys, and failing heart) that were key to the understanding of why heart failure progressively worsened over time and to effective new treatments. It was realized that inappropriate activation of a key hormonal pathway, the renin-angiotensin-aldosterone system (RAAS), occurs in patients with heart failure, contributing to the progressive worsening I have mentioned and, ultimately, death. One of my most formative experiences as a young Cardiology trainee was seeing Dr Karl Swedberg, as he was then, from Gothenburg University present the results of the first trial (CONSENSUS) in heart failure to show that we could reduce the risk of death in this terrible illness. 3 That trial, conducted in around 250 people with very advanced heart failure, showed that a drug which blocked the RAAS, enalapril, had a dramatic and early effect on mortality. Later another, larger, trial showed that the same drug also improved survival in patients with less severe symptoms; one of the leaders of that trial was Salim Yusuf ( Figure 1 ). 4 Another less well publicized discovery around that time was that the heart was not just a mechanical pump but also an endocrine organ that secreted peptide hormones which stimulated the kidneys to excrete sodium and water. 5 I was fascinated by this discovery and in 1986 went to work with one of the pioneers studying these newly described hormones in humans, Professor Allan Struthers at the University of Dundee in Scotland. We showed that these natriuretic peptides, as well as promoting urine production by the kidneys, also inhibited the RAAS. 6 -8 We also hypothesized that because of these actions, boosting natriuretic peptide levels might be a useful way to treat patients with heart failure. 8 While working in Dundee I heard that Dr Henry Dargie in Glasgow was working with a new drug that blocked an enzyme (neutral endopeptidase or neprilysin) which breaks down natriuretic peptides (thereby increasing natriuretic peptide levels). 9 -11 Because of that I moved to Glasgow in 1988 in the hope of becoming involved in the further development of this exciting new compound. Unfortunately, for reasons we did not understand at the time, the effect of this agent was not sustained over time and it was abandoned. However, that story did not end there, as I will come back to. I pursued additional lines of research, finding that angiotensin II could be produced in human tissues by non-angiotensin-converting enzyme (ACE) pathways. 12, 13 This provided some of the rationale to add a new type of RAAS antagonist, an angiotensin receptor blocker, to an ACE inhibitor and that an ARB might be as good as or even better than an ACE inhibitor. With Karl Swedberg, Marc Pfeffer (Brigham and Women's Hospital, Boston), Christopher Granger (Duke University), and Salim Yusuf I conducted a series of trials in patients with chronic heart failure (CHARM) and a large trial in patients with heart failure after myocardial infarction (VALIANT, where I became friends with Rob Califf, Lars Køber, Aldo Maggioni, Eric Velazquez, Faiez Zannad, among others) using two of these new drugs.
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Together we showed that ARBs were an effective alternative to ACE inhibitors (important because some patients cannot tolerate an ACE inhibitor) and that in heart failure adding an ARB to an ACE inhibitor further reduced the risk of death and hospital admission. With ACE inhibitors and b-blockers which had also been shown to be of benefit in heart failure, we now had three drugs that used together led to much better outcomes for our patients with heart failure than could have been dreamt of twenty years early. I had also been interested in a different type of RAAS blocker spironolactone, which is a mineralocorticoid receptor antagonist (MRA) blocking the actions of aldosterone rather than angiotensin II. Spironolactone had been shown by Bert Pitt (Ann Arbor Michigan) and Faiez Zannad (Nancy, France) to reduce the risk of death in patients with severe heart failure when added to an ACE inhibitor but this was before we had learnt about the value of b-blockers and ARBs (the famous RALES trial). 18 I and others showed that MRAs also seemed to have beneficial actions in patients with milder symptoms and was lucky enough to team up with Drs Pitt, Zannad, Swedberg, and Henry Krum from Melbourne in Australia among others, to lead a new mortality/morbidity trial with the MRA eplerenone in patients with heart failure and mild symptoms, by this stage adding the MRA not only to an ACE inhibitor but also a b-blocker. 19, 20 We were delighted to be able to show that this treatment led to a striking improvement in outcome with both an improvement in survival and decrease in hospital admissions. Now we had a treatment that was even better than an ARB when added to an ACE inhibitor and b-blocker and a triad of treatments capable of transforming the lives of all patients with this type of heart failure ( Figure 2 ). More recently I had another opportunity to pursue the hypothesis that enhancing the actions of natriuretic peptides might be beneficial in heart failure. By the late 1990s we had learnt that neprilysin inhibition had to be combined with an RAAS blocker to express its full therapeutic potential and that the better RAAS blocker might be an ARB rather than an ACE inhibitor. 21 With another friend and colleague of many years standing, Milton Packer, I went on to lead a trial using the new strategy of using a combined angiotensin receptor neprilysin inhibitor (ARNI), comparing this head-to-head with the now "standard-of-care" ACE inhibitor enalapril. 22 -25 We were fortunate to work again with Karl Swedberg and other friends including Jean Rouleau (Montréal), Scott Solomon (Boston, MA), and Mike Zile (Charleston, SC) and colleagues from Novartis. Could we beat and replace a current gold-standard treatment that had revolutionized the management of heart failure 20 years earlier and had not been bettered since? Last year we showed that this novel approach lowered the risk of death and hospital admission even further, in fact effectively doubling the mortality benefit of enalapril the drug that had opened up a new era of hope for patients with heart failure back in 1987 at the start of my career in Cardiology (Figure 2 ). Now we are on the cusp of having available just three drugs that can make a fundamental difference to the lives our patients with heart failure and their loved ones. Treatment with b-blocker, an MRA and an ARNI together will reduce the risk of premature death to around a third to a quarter of what it was when I qualified from medical school, as well as reduce the crippling symptoms and frequent hospital admissions suffered by patients with heart failure. It has taken us 30 years to reach this point and there have been many failures along the way (Figure 3) . However, we have got to where we are because of the massive collaborative effort between doctors, governments, and industry across the world. The world community of clinical trialists is a remarkable one that has changed the way we practice medicine for the better. But, of course, fundamentally key to this venture has been our patients who have trusted us, literally with their lives, in agreeing to participate in clinical trials. We still face challenges. Implementation of effective treatments is still suboptimal for reasons that we do not always understand. 26 In some countries it is because the drugs are still not affordable by many but in others it is because of lack of knowledge, education, or other factors. Here guidelines, organization and audit of care have the potential to make a huge difference and I am a passionate advocate of promoting the uptake of evidence-based medicines through these approaches. 27 -29 Another important finding I and others, including my good friend Simon Stewart from Melbourne, demonstrated many years ago in a randomized trial is that specialist nurses can improve outcomes for patients with heart failure in part through careful implementation of effective therapies. 30, 31 Finally, there is another less common but still important type of heart failure-heart failure with preserved ejection fraction where the problem is with the relaxation and filling of the heart and not its contraction and emptying. Sadly, to date all our efforts to help patient with this problem have failed, although we have not given up and continue to look for a breakthrough. Improving outcomes in heart failure importance of heart failure as one of the increasingly common medical problems world-wide today.
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